Washington: Scientists have identified a promising drug candidate for the treatment of rare but severe conditions, and has the potential to threaten the lives of children infected with the SARS-COV-2 virus, which causes Covid-19 Multi-inflammatory syndromes in children (MIS-C) usually develop weeks for months after children experience a covid-19 case that is light or even asymptomatic, the researchers said MIS-C leads to high fever and hyperinflammation responses that can affect many organs, including the heart, brain and gastrointestinal organs, they said.
Previous research by researchers at Massachusetts (MGH) General Hospital and Brigham and Women’s Hospital (BWH) in the US show that in the case of MIS-C, the SARS-COV-2 virus can remain in the intestine for weeks after months After months after months after infection When SARS-COV-2 is present in the intestine, disturbed mucosal barriers can allow small viral particles, such as protein surges, to enter the bloodstream, which causes infections such as Covid-19 and in rare cases, the hyperinflammation response triggers mis-c .
The SARS-COV-2 virus uses a surge protein to enter and infect cells “Work collaboratively, we have been able to show that viral particles that remain in the old gut after Covid-19 infection can incite MIS-C,” said David Walt, a senior writer of research published in the journal Exploration Critical Care Building this important discovery, we want to see whether treatment with drugs developed for other conditions – Celiac disease – can help resolve symptoms in children who experience MIS-C, Walt said.
The team provided Larazotide acetate four children who were very painful age 3 to 17 were treated for mis-c This study shows that Larazotide reduces the release of zonulin, molecules that can cause increased intestinal permeability and disturbed mucosal barriers, thick slime layers in the intestine The researchers compared the clinical results of four children who received Larazotide Plus steroids and the Globulin Immunus Intravent (IVIG) to 22 children who only received steroids and IVIG.
Children who receive four oral daily doses of Larazotide Acetate have a resolution of gastrointestinal symptoms that are much faster and live in hospitals that are a little shorter, they said The study also found that serum levels of surge proteins dropped much faster in children treated with Larazotide, cleaning from blood in one day, versus 10 days for children not treated with drugs “This finding shows that Larazotide can provide safe and useful adjuvant therapy for MIS-C treatment,” said the researchers The expansion of clinical trials is needed to ensure the clinical impact of Larazotide in MIS-C,” he added.